SEC Form 4 · accession 0001209191-18-050574
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven Shak
Officer — Chief Scientific Officer
Period of report
Sep 10, 2018
Accepted (ET)
Sep 11, 2018 · 7:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 10, 2018 | M | 5,500 | $27.33 | A | 342,241 | D | |
| Common StockF2,F3,F4,F1 | Sep 10, 2018 | S | 3,637 | $62.6618 | D | 338,604 | D | |
| Common StockF2,F3,F5,F1 | Sep 10, 2018 | S | 1,863 | $63.818 | D | 336,741 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $17.33 | Sep 10, 2018 | M | 5,500 | D | — | Dec 4, 2018 | Common Stock | 5,500 | 12,500 | D |
Explanation of responses
- F1Includes an aggregate of 13,320 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $62.29 to $63.24.
- F5Represents weighted average sale price. Actual sale prices ranged from $63.42 to $64.12.
- F6The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.